Benefits
Low calorie sweetness and the FDA sugar labeling rule
Sukré® provides sweetness at ~70% of sucrose intensity with only 0.4 kcal/g caloric contribution — and per FDA guidance, allulose can be excluded from total and added sugar labeling. That labeling rule is a regulatory fact about how allulose is counted on a package. It is not itself evidence of a health benefit.
Lower postprandial blood glucose in healthy adults
A systematic review and meta-analysis of human trials (PMID 37023000) concluded that D-allulose attenuates postprandial blood glucose in healthy humans, at both 5 g and 10 g. The proposed mechanism is competitive inhibition of intestinal alpha-glucosidase enzymes, which slows the breakdown of dietary carbohydrate into absorbable glucose. This is a short-term response measured after a meal in healthy people rather than evidence of long-term blood sugar control, and none of the studies cited here tested Sukré itself.
Body fat reduction in one preliminary trial
The body composition evidence on this page is a single trial rather than a meta-analysis. PMID 29385054 is a randomized, double-blind, placebo-controlled study in 121 Korean adults aged 20 to 40 with a BMI of 23 or above, and the authors call it a preliminary study in the title. Body fat percentage and body fat mass fell, and the higher dose group (7 g twice daily) also showed decreases in BMI and in abdominal and subcutaneous fat on CT imaging. The fat oxidation and gut microbiome explanations are hypotheses: no study cited on this page measured fat oxidation or Akkermansia muciniphila in people.
Mechanism of action
Alpha-glucosidase inhibition
Allulose competitively inhibits intestinal brush border alpha-glucosidases (maltase, sucrase) — enzymes that break down complex carbohydrates into glucose for absorption. This mechanism reduces glucose absorption rate and postprandial glycemia. No reference on this page compared allulose with any prescription medication. Unabsorbed allulose that reaches the colon has been proposed to encourage growth of Akkermansia muciniphila, a mucus-layer bacterium, but no study cited on this page measured gut bacteria, insulin sensitivity or gut permeability in people.
Clinical trials
Systematic review and meta-analysis of human trials measuring the effect of D-allulose on postprandial blood glucose (PMID 37023000). The abstract of the cited paper does not state how many trials were pooled, and it does not report body composition outcomes.
Healthy adults. The cited meta-analysis states its conclusion for healthy humans, so it is not a source for effects in people with metabolic syndrome.
The cited meta-analysis concludes that D-allulose attenuates postprandial blood glucose in healthy humans, at both 5 g and 10 g. The figures previously shown on this card, including a 0.44 mmol/L glucose reduction, a 0.58 kg body weight reduction, and tolerance up to 54 g per day, do not appear in the cited paper and should not be treated as established. Two other references on this page are not covered by this card: an acute feeding equivalence trial of small doses of fructose and allulose (PMID 29890724), and an acute study of D-allulose and erythritol (PMID 36678329) in which D-allulose had no effect on blood lipids, uric acid or hsCRP.